Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancer
March 21, 2021 5:00 pmResponses in 37% of patients with AVB-500, higher without prior bevacizumab.
By Charles Bankhead
More than a third of patients with platinum-resistant ovarian cancer had objective responses to chemotherapy plus a small-molecule inhibitor that targets resistance-associated signaling, a preliminary study … Read more